Medistem's Endometrial Regenerative Cell Discovery Publication
Receives BioMed Central's Article of the Year Award
March 20, 2008: 08:10 AM EST
Medistem Laboratories, Inc. (OTCBB: MDSM) is pleased to announce its
recent co-authored article entitled, "Endometrial regenerative cells:
a novel stem cell population" received BioMed Central's research
article of the year in medicine award. The award recognizes
excellence in research that has been made universally accessible
through open access publication in one of BioMed Central's > 170 peer
reviewed scientific journals. The award was presented to Medistem's
CEO Thomas Ichim and Dr. Xiaolong Meng at the Royal Society of
Medicine in London, England. The publication is freely available at
http://www.translat
"We are extremely proud of the international recognition our
scientists and collaborators are receiving for the discovery of this
new type of stem cell," said Dr. Neil Riordan, President of
Medistem. "We believe that these cells, which we have termed
endometrial regenerative cells (ERC), offer a novel way of
circumventing the medical and ethical issues posed by embryonic stem
cells today."
Medistem owns intellectual property associated with endometrial
regenerative cells and is currently developing a pipeline of
therapeutic products around them. Medistem's lead product is based on
preventing amputation through restoring blood flow to the limbs of
patients with diabetes and advanced peripheral artery disease.
"The ERC population appears to be superior to other stem cell types.
These cells do not require matching with the recipient, they home to
areas of injury or tissue damage, and they can become most of the
tissue types found in the body," said Dr. Xiaolong Meng, lead author
of the article, Associate Director of the Bio-Communications Research
Institute, and Medistem collaborator.
About Medistem Laboratories
Medistem Laboratories is a biotechnology company founded to develop
and commercialize technologies related to adult stem cell extraction,
manipulation, and use for treating inflammatory and degenerative
diseases. The company's lead product, the endometrial regenerative
cell (ERC), is a "universal donor" stem cell derived from the
menstrual blood that possesses the ability to differentiate into nine
tissue types, produce large quantities of growth factors, and a large
proliferative capacity. Due to Medistem's relationships and
collaborative efforts with respected institutions, Medistem believes
it is well positioned to be a leading developer of adult stem cell
products. .
Cautionary Statement
This document does not constitute an offer to sell or a solicitation
of an offer to buy any of our securities. This document contains
certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements may include projections of matters that affect revenue,
the ability to develop or license certain technologies and receive
associated licensing fees; operating expenses or net earnings;
projections of capital expenditures; projections of growth; hiring
plans; plans for future operations; financing needs or plans; plans
relating to the company's products and services; and assumptions
relating to the foregoing.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
information.
Some of the important factors that could cause the company's actual
results to differ materially from those projected in forward-looking
statements made by the company include, but are not limited to, the
following: the company's ability to anticipate future license fees,
technology development limitations, intense competition, risk of
business interruption, management of rapid growth, need for
additional financing, regulatory approvals and requirements,
dependence on key personnel and research, management and other
administrative costs.
These factors are discussed in greater detail in the company's
quarterly and annual periodic reports, all as filed with the
Securities and Exchange Commission.
Contact:
Medistem Laboratories
Chris McGuinn
602-318-3535
http://www.medistem
http://money.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment